Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma

Cancer Science

Volumn 104, Issue 5, 2013, Pages 647-650

  Ishida, Takashi ^a   Ito, Asahi ^a   Sato, Fumihiko ^a   Kusumoto, Shigeru ^a   Iida, Shinsuke ^a   Inagaki, Hiroshi ^a   Morita, Akimichi ^a   Akinaga, Shiro ^b   Ueda, Ryuzo ^c  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; ITRACONAZOLE; LANSOPRAZOLE; METHYLPREDNISOLONE; MOGAMULIZUMAB; PREDNISOLONE; SOBUZOXANE; TRANSCRIPTION FACTOR FOXP3;

AGED; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG ERUPTION; EMERGENCY PATIENT; FEMALE; HUMAN; LEUKEMIA REMISSION; LIMIT OF DETECTION; LIQUEFACTION; LYMPHOCYTE COUNT; ORAL ERUPTION; PRIORITY JOURNAL; RASH; REGULATORY T LYMPHOCYTE; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; T CELL LEUKEMIA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; STEVENS-JOHNSON SYNDROME;

EID: 84876414545     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12116     Document Type: Article

References (15)

1. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia-lymphoma. Int J Hematol 2011; 94: 443-52.
2. Ishii T, Ishida T, Utsunomiya A et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16: 1520-31.
3. Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 1591-8.
4. Ishida T, Joh T, Uike N et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase ii study. J Clin Oncol 2012; 30: 837-42.
5. Tsukasaki K, Utsunomiya A, Fukuda H et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-64.
6. Sonoda J, Koriyama C, Yamamoto S et al. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci 2004; 95: 596-601.
7. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-15.
8. Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S. Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol 2005; 35: 1722-30.
9. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182: 8071-9.
10. Iellem A, Mariani M, Lang R et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194: 847-53.
11. Ishida T, Ishii T, Inagaki A et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-22.
12. + regulatory T cells in systemic sclerosis and other rheumatic diseases. Expert Rev Clin Immunol 2011; 7: 499-514.
13. Campbell JJ, Haraldsen G, Pan J et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400: 776-80.
14. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13: e32-42.
15. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102: 44-50.